Opus Genetics, Inc. lost $0.80 per diluted share in fiscal year 2025. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a loss of $1.56 per diluted share. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Opus Genetics, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$0.80
Ticker history: OCUP became
IRD
(Opus Genetics, Inc.) on .
Earlier news and filings retain their original names and dates.
View OCUP history.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Opus Genetics, Inc. lost $0.80 per diluted share in fiscal year 2025.
Opus Genetics, Inc. (IRD) reported a loss of $1.56 per diluted share over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
Across the 15 fiscal years this page covers, Opus Genetics, Inc. (IRD) diluted earnings per share went from -$0.12 in fiscal year 2011 to -$0.80 in fiscal year 2025.
Opus Genetics, Inc. (IRD) reported -$0.46 in diluted earnings per share in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Opus Genetics, Inc. (IRD) reported on that line in every period on record.